| advanced breast cancer (metastatic) | versus no bevacizumab No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Martin (motesanib), 2011 | motesanib + paclitaxel vs paclitaxel | | | |
| Trial | Treatments | Patients | Method |
|---|
| Martin (motesanib), 2011 | motesanib 125 mg orally once per da (n=91) vs. placebo (n=94)
| patients with untreated HER2-negative metastatic breast cancer
| double-blind Sample size: 91/94 Primary endpoint: FU duration:
|
|
| lung cancer (metastatic) | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Scagliottib MONET1, 2012 | carboplatin (area under the curve, 6 mg/ml · min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (n=-9) vs. (n=-9) | patients with advanced nonsquamous non-small-cell lung cancer | double-blind Sample size: -9/-9 Primary endpoint: OS FU duration: phase III |
|
